AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23249916
Drug: No maternal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No maternal antiretroviral treatment
Trial: 19564304
Drug: Moderate-dose methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose methylphenidate (0.6 mg/kg; 20 mg twice daily maximum)
Trial: 19564304
Drug: Low-dose methylphenidate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methylphenidate (0.3 mg/kg; 10 mg twice daily maximum)
Trial: 17083767
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination therapy with methotrexate, sulphasalazine, and tapered high dose of prednisone
Trial: 17083767
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination therapy with methotrexate and infliximab
Trial: 17083767
Drug: Step up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step up to combination therapy starting with methotrexate
Trial: 9202949
Drug: 6% glucose-electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% glucose-electrolyte solution (GS)
Trial: 9202949
Drug: 6% maltodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% maltodextrin solution
Trial: 9202949
Drug: 6% maltodextrin-electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% maltodextrin-electrolyte solution
Trial: 3440105
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg) given as enteric-coated granules
Trial: 3440105
Drug: Antacid (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid (10 ml, buffering capacity 56.6 mmol 10 ml‐1)
Trial: 21920001
Drug: Mebeverine 135
RxNorm normalized name: mebeverine 135 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebeverine 135 mg three times daily
Trial: 18665032
Drug: Mupirocin ointment
RxNorm normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mupirocin ointment therapy
Trial: 16715358
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of pertuzumab (420 or 1050 mg)
Trial: 16715358
Drug: Weight-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based dosing (0.5-15 mg/kg)
Trial: 12525510
Drug: BSA-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSA-based dosing
Trial: 12559533
Drug: Clopidogrel 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 1 x 300 mg as a loading dose, and 1 x 75 mg per day thereafter
Trial: 9424002
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose radiation therapy (60 Gy continuously) and daily cisplatin (6 mg/sqm/day)
Trial: 8276050
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ramipril and propranolol
Trial: 9629648
Drug: Sequential test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential test
Trial: 30611113
Drug: The Pink
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Pink Kit Method for Birthing Better® (CKT, 2001), a multi-media, skills-based and self-directed childbirth preparation programme.
Trial: 24907502
Drug: Medium-dose oral
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose oral budesonide suspension (OBS)
Trial: 24907502
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral budesonide suspension (OBS)
Trial: 24907502
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral budesonide suspension (OBS)
Trial: 16990383
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of autologous mononuclear bone marrow cells (BMC)
Trial: 17130431
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered CC chemokine receptor 1 (CCR1) antagonist
Trial: 10912264
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of nasal allergy for a period of at least four months
Trial: 2883406
Drug: 0.6 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 g/kg intravenous immunoglobulin
Trial: 2883406
Drug: 0.2 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g/kg intravenous immunoglobulin
Trial: 24215475
Drug: Topical 5-aminolevulinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5-aminolevulinic acid (ALA) photodynamic therapy (PDT) with light dose of 70 J/cm2
Trial: 24215475
Drug: Topical 5-aminolevulinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5-aminolevulinic acid (ALA) photodynamic therapy (PDT) with light dose of 100 J/cm2
Trial: 12115321
Drug: Perilymphatic recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perilymphatic recombinant IL‐2 (rIL‐2) administered at 5000 units daily for 10 days before surgery and monthly for 1 year after surgery.
Trial: 7579136
Drug: 0.15 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 IU insulin kg‐1
Trial: 1537779
Drug: Nortriptyline (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline (active treatment)
Trial: 22613136
Drug: abciximab infusion
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: abciximab infusion
Trial: 17697305
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 microg/kg bolus and infusion at a rate of 0.7 microg/kg/h)
Trial: 11642510
Drug: Serum transferrin
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum transferrin receptor (s‐TfR) levels in RA patients
Trial: 11367653
Drug: Feiyan Chuansou
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feiyan Chuansou Oral Liquid (FCOL)
Trial: 7882780
Drug: St. Thomas
RxNorm normalized name: St. Thomas lidpod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. Thomas group (CC)
Trial: 2975567
Drug: Three times
RxNorm normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times daily pen regimen with human ultralente at night
Trial: 2975553
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily insulin regimen
Trial: 25952532
Drug: Basal-prandial insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal-prandial insulin (stepwise addition of insulin glulisine)
Trial: 25952532
Drug: Premixed insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premixed insulin (insulin aspart/insulin aspart protamine 30/70 starting with 6IU twice daily)
Trial: 23314694
Drug: 2.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 μg/kg fentanyl
Trial: 23314694
Drug: 4.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 μg/kg fentanyl
Trial: 20498403
Drug: Bevacizumab 15
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 15 mg/kg plus docetaxel 100 mg/m(2)
Trial: 20498403
Drug: Bevacizumab 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 7.5 mg/kg plus docetaxel 100 mg/m(2)
Trial: 20498403
Drug: Docetaxel 100
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 100 mg/m(2) plus placebo
Trial: 20150572
Drug: Bevacizumab 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 7.5 mg/kg
Trial: 19098989
Drug: Monthly artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly artesunate plus amodiaquine (AS+AQ)
Trial: 15908136
Drug: Self-reported substance
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported substance abuse treatment contact after enrollment
Trial: 10720292
Drug: Modafinil (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (both doses)
Trial: 1465034
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg 17 beta‐oestradiol and different doses of progesterone (50, 100 or 200 mg)
Trial: 29907581
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg (EMPA-REG H2H-SU trial)
Trial: 26465829
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (233 mg zinc gluconate containing 30 mg zinc) for 6 weeks
Trial: 17543812
Drug: Levobupivacaine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine infusion (50 hours)
Trial: 17543812
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (50 hours)
Trial: 11982742
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 60 mg day -1
Trial: 10441040
Drug: 25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/kg (b.w.) of nicotinamide (NA)
Trial: 10441040
Drug: 50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg (b.w.) of nicotinamide (NA)
Trial: 10441040
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of nicotinamide (25 mg/kg and 50 mg/kg)
Trial: 2077983
Drug: Midazolam 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.4 mg/kg
Trial: 2077983
Drug: Diazepam 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.75 mg/kg
Trial: 348536
Drug: Metopimazine 30
RxNorm normalized name: metopimazine
DrugBank: Metopimazine (DB13591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metopimazine 30 mg/day or 15 mg/day
Trial: 348536
Drug: Metopimazine 45
RxNorm normalized name: metopimazine
DrugBank: Metopimazine (DB13591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metopimazine 45 mg/day
Trial: 19236356
Drug: Buprenorphine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine treatment for heroin dependence
Trial: 10742705
Drug: Exercise programme
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise programme (once weekly sessions for 12 weeks)
Trial: 9475306
Drug: Glucose oral
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose oral rehydration solution (ORS)
Trial: 30858203
Drug: Daptomycin plus
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomycin plus Ceftaroline (DAPCPT) - 6 to 8 mg/kg of body weight per day of DAP and 600 mg intravenous CPT every 8 hours (n 17)
Trial: 30858203
Drug: Standard monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard monotherapy - Vancomycin (VAN; dosed to achieve serum trough concentrations of 15 to 20 mg/liter; n 21) or 6 to 8 mg/kg/day DAP (n 2) (n 23 total)
Trial: 30858203
Drug: Daptomycin plus
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomycin plus Ceftaroline (DAPCPT) - among patients with IL-10 concentration of 5 pg/ml (n 14)
Trial: 30858203
Drug: Standard monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard monotherapy - among patients with IL-10 concentration of 5 pg/ml (n 19)
Trial: 29993140
Drug: Standardised oral
RxNorm normalized name: standardized senna concentrate Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised oral health examination by registered dental hygienists
Trial: 22686185
Drug: 18 months
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 18 months of weekly psychoanalytic psychotherapy, manualised and fidelity‐assessed using the Psychotherapy Process Q‐Sort.
Trial: 22686185
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual, managed by the referring practitioner.
Trial: 20830664
Drug: Desvenlafaxine (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine (50, 100, 200, or 400 mg/d)
Trial: 18555464
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose chemotherapy (HDCT) with melphalan 200 mg/m² and autologous peripheral stem cell transplantation (APSCT)
Trial: 18555464
Drug: Thalidomide maintenance
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide maintenance therapy at 100 mg/day
Trial: 7586952
Drug: Phentolamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine (10 mg, intravenous)
Trial: 7586952
Drug: Prazosin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (5 mg, orally)
Trial: 7586952
Drug: Nicardipine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (2 micrograms/kg/min, continuous intravenous infusion)
Trial: 2254715
Drug: Multiple injections
RxNorm normalized name: sodium acetate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple injections (MI) with human isophane insulin
Trial: 2254715
Drug: Multiple injections
RxNorm normalized name: sodium acetate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple injections (MI) with human ultralente insulin
Trial: 2254715
Drug: Intensified therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified therapy (CSII and MI)
Trial: 2254715
Drug: Intensified insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensified insulin therapy (CSII and MI)
Trial: 7029388
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% aqueous indomethacin
Trial: 31646414
Drug: High-dose spinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose spinal analgesia (levobupivacaine 7.5 mg plus sufentanil 2.5 μg)
Trial: 31646414
Drug: Low-dose spinal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose spinal analgesia (levobupivacaine 3.75 mg plus sufentanil 2.5 μg)
Trial: 31646414
Drug: High-dose spinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose spinal analgesia during laparoscopy
Trial: 31646414
Drug: Low-dose spinal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose spinal analgesia during laparoscopy
Trial: 28295463
Drug: RG-101 2
RxNorm normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG-101 2 mg/kg (n = 14)
Trial: 28295463
Drug: RG-101 4
RxNorm normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG-101 4 mg/kg (n = 14)
Trial: 23685845
Drug: Sildenafil treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil treatment in ED/DM group
Trial: 26337285
Drug: Insulin initiation
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin initiation checklist
Trial: 25220898
Drug: Pain that
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain that at least moderately interfered with daily living
Trial: 8246275
Drug: Clomipramine 25
RxNorm normalized name: clomiPRAMINE 25 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine 25 mg
Trial: 7562355
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (nonresorbable barrier)
Trial: 2075848
Drug: Attending three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attending three weekly support meetings during the program
Trial: 7033946
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 200 mg metoprolol and 2.5 mg indapamide
Trial: 31980886
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine infusion (1.5 mg/kg bolus followed by 1.5 mg/kg/h continuous infusion)
Trial: 31796179
Drug: Afoxolaner (2.7-6.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afoxolaner (2.7-6.9 mg/kg, PO)
Trial: 31796179
Drug: Ivermectin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (300 μg/kg, SC)
Trial: 31796179
Drug: Afoxolaner (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afoxolaner (monthly treatment for heavy infestations)
Trial: 29090299
Drug: Palm oil
RxNorm normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palm oil (PO, 22.25 g)
Trial: 29090299
Drug: Rice bran
RxNorm normalized name: Rice bran
DrugBank: Rice bran (DB14361)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice bran oil (RBO, 22.25 g)
Trial: 29090299
Drug: Palm oleogel
RxNorm normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palm oleogel (PG, 22.25 g oil + 2.75 g EC)
Trial: 29090299
Drug: Rice bran
RxNorm normalized name: Rice bran
DrugBank: Rice bran (DB14361)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice bran oleogel (RBG, 22.25 g oil + 2.75 g EC)
Trial: 19394503
Drug: Nicardipine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (0.5 microg/kg/min continuous infusion)
Trial: 15232500
Drug: 5,000 U
RxNorm normalized name: Decara 25,000 UNT Vegicaps
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,000 U of Botulinum toxin type B (BTX-B) treatment
Trial: 9839762
Drug: Donepezil +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil + Cimetidine (5 mg + 800 mg)
Trial: 2631519
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 1200 mg/day
Trial: 2631519
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of acetylsalicylic acid (ASA, 1050 mg/day) and dipyridamole (D, 150 mg/day)
Trial: 1023953
Drug: Aluminium hydroxide
RxNorm normalized name: Aluminium hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminium hydroxide 40 ml
Trial: 1023953
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate 30 ml
Trial: 1023953
Drug: Magnesium trisilicate
RxNorm normalized name: Magnesium Trisilicate
DrugBank: Magnesium trisilicate (DB09281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium trisilicate 30 ml
Trial: 1023953
Drug: Diazepam 10
RxNorm normalized name: diazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 10 mg alone
Trial: 22999847
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (subacromial, intra-articular, intra-articular combined with subacromial)
Trial: 22999847
Drug: Medication (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (control group IV)
Trial: 17163358
Drug: Calcitriol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol 1.5 mcg/die plus hydrochlorothiazide
Trial: 9322806
Drug: tolrestat (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolrestat (200 mg daily)
Trial: 3919803
Drug: Cimetidine 1
RxNorm normalized name: cimetidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 1 g daily for one month
Trial: 3919803
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg daily for one month
Trial: 20925642
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg twice daily)
Trial: 20925642
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg twice daily) + Topical honey ointment
Trial: 20925642
Drug: Standard burn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard burn treatment (Control group)